Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas : Episode 4

Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

Feb 7, 2023

Loretta J. Nastoupil, MD
Marc S. Hoffman, MD

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

EP: 1.Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

EP: 2.Currently Available Treatment Options for Patients With R/R DLBCL

EP: 3.ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

EP: 4.Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

EP: 5.Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL

EP: 6.Available Treatment Options for Relapsed/Refractory Follicular Lymphoma (R/R FL)

EP: 7.CAR T-Cell Therapy for Patients With R/R FL

EP: 8.Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Related Videos

Jeffery Zonder, MD

Jeffery Zonder, MD

Abhinav Deol, MD

Veronika Bachanova, MD, PhD

Eunice Wang, MD

Craig Sauter, MD

Lisa A. Carey MD, ScM, FASCO

Patrick I. Borgen, MD

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C)

Steven J. Chmura, MD, PhD

Related Content

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

Related Content

Image Credit: ©freshidea - stock.adobe.com

New Model Predicts Long-term Response to CAR T-cell Therapy in B-cell Lymphoma

March 24th 2023

$Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma$

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Axi-Cel Elicits Benefit in LBCL | Image Credit: ©Dr_Microbe - stock.adobe.com

Second-line Axi-cel Elicits OS Benefit in Relapsed/Refractory LBCL

March 21st 2023

$FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL$

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

Mayur Narkhede, MD

Siltuximab Resolves CRS/ICANS After CAR T-cell Therapy for Hematologic Malignancies

March 16th 2023

Nirav N. Shah, MD

Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL

March 15th 2023

Latest Conference Coverage

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.